Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Centene Corp (NYSE:CNC) experienced a dramatic sell-off in premarket trading on July 2, 2025, with shares plummeting 28.96% to $40.24 as of 7:14 AM EDT. The healthcare giant’s stock collapse followed the company’s unexpected announcement on July 1st that it was withdrawing its entire 2025 financial guidance due to significantly worse-than-expected marketplace conditions. The withdrawal represents a major setback for the managed care provider, which serves over 1 in 15 Americans through government-sponsored healthcare programs.
Guidance Withdrawal Shocks CNC Investors
Centene’s decision to completely withdraw its 2025 GAAP and adjusted diluted earnings per share guidance sent shockwaves through the healthcare sector.
The company cited preliminary data from 22 of its 29 marketplace states, representing 72% of its marketplace membership, which revealed that overall market growth was lower than expected while aggregate market morbidity was significantly higher than anticipated. This data discrepancy forced management to reassess their financial projections entirely.
The most concerning aspect of the announcement was the company’s preliminary estimate of an approximately $1.8 billion reduction in net risk adjustment revenue transfer expectations, translating to roughly $2.75 per share impact on adjusted diluted earnings. This massive adjustment reflects underlying deterioration in the health insurance marketplace that was not anticipated in the company’s original 2025 planning assumptions. Additionally, Centene indicated that data from its remaining seven marketplace states could result in further negative adjustments.
Beyond marketplace challenges, the company also disclosed that its Medicaid business experienced a step-up in medical cost trends, particularly in behavioral health, home health, and high-cost drugs. These cost pressures were most pronounced in key markets like New York and Florida, where service carve-ins occurred without sufficient rate adjustments or risk protections.
CNC Stock Slides in Premarket Trading After Firm Withdraws Guidance
The market’s reaction to Centene’s guidance withdrawal was swift and severe, with the stock falling from a previous close of $56.65 to $40.24 in premarket trading, representing a loss of $16.40 per share or 28.96%.
This dramatic decline wiped out approximately $8.3 billion in market capitalization based on the company’s 497 million shares outstanding. The premarket selloff occurred at 7:14 AM EDT, indicating institutional investors were quickly reassessing their positions ahead of regular trading hours.
CNC’s valuation metrics highlight the extent of the market’s concerns about the company’s near-term prospects. Trading at just 8.36 times trailing twelve-month earnings with a forward P/E of 7.79, the stock now reflects significant skepticism about management’s ability to navigate the challenging marketplace environment.
The company’s analyst price targets range from $61 to $92, with an average target of $76.50, suggesting potential upside if Centene can successfully implement corrective measures for 2026.
Looking at broader performance trends, Centene has struggled significantly over recent years, with negative returns of 6.49% year-to-date, -13.30% over one year, and a devastating -34.29% over three years, dramatically underperforming the S&P 500’s positive returns during the same periods.
The company’s ability to recover will largely depend on its success in refiling 2026 marketplace rates to reflect the higher morbidity baseline and implementing effective cost management strategies across its Medicaid operations.
***
Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.
This article was originally published on The Tokenist. Check out The Tokenist’s free newsletter, Five Minute Finance, for weekly analysis of the biggest trends in finance and technology.